The patient was a 64-year-old woman who had undergone partial enterectomy for a small
intestinal tumor in August 2005, and gastrointestinal stromal tumor (GIST) was diagnosed …

We report 2 cases of successful reintroduction of mesylate imatinib for gastrointestinal
stromal tumor (GIST) after drug-induced pneumonitis. Both of them were women in the fifth …

Introduction: Imatinib is approved for the treatment of chronic myeloid leukemia and for
gastro intestinal stromal tumors. It is generally well tolerated with mild common toxicities …

Interstitial pneumonitis related to imatinib (Glivec) shows various radiological patterns but
usually improves after imatinib withdrawal or subsequent corticosteroid treatment (1-4) …

Introduction Imatinib has led to a phenomenal progress in the treatment of GIST. A rare and
lesser-known side effect of imatinib is pneumonitis, an uncommon multicausal interstitial …

Gastrointestinal stromal tumors (GISTs) are rare mesenchymal neoplasms that may affect
any portion of the gastrointestinal tract. Surgical resection was previously considered the …

Imatinib-mesylate (Gleevec, Glivec) is a protein-tyrosine kinase inhibitor that inhibits the Bcr-
Abl tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib is …

We describe a patient who had a metastatic gastrointestinal stromal tumor (GIST) after
previous failed extensive therapy, including multiple surgeries and hepatic artery …

Imatinib mesylate (IM) is a tyrosine kinase inhibitor that targets protein kinase, such as BCR-
ABL, KIT, and platelet derived growth factor receptor-A and B. The efficacy and safety of IM …

Background Imatinibmesylate (imatinib) is a small molecule tyrosine kinase inhibitor
administered to patients with chronic myelogenous leukemia and gastrointestinal stromal …